The epidemiology of infections was studied in a retrospective cohort of 446 recipients of bone marrow transplants (BMTs; 92 of which were allogeneic and 354 of which were autologous) during 1993-1996. Infections that were microbiologically documented in 274 recipients included bacteremia, urinary tract infections, cytomegalovirus viremia, fungemia, invasive aspergillosis, and catheter-related infections. During the period of neutropenia, no differences were found between recipients of allogeneic BMTs and recipients of autologous BMTs with regard to the incidence and the nature of infection. After patients underwent engraftment, bacteremia, cytomegalovirus viremia, and invasive aspergillosis were significantly more common in recipients of allogeneic BMTs than in recipients of autologous BMTs. Deaths caused by infection were uncommon and were mainly the result of invasive aspergillosis. Therefore, empirical antimicrobial therapy should be the same for recipients of both allogeneic and autologous BMTs during the period of neutropenia; after engraftment, more attention should be paid to the risk of infection in allogeneic BMT recipients, particularly with regard to detection and prevention of invasive aspergillosis.
transplantation remains associated with serious complications, such as graft-versus-host disease (GVHD), graft failure, interstitial pneumonitis, veno-occlusive disease of the liver, and nosocomial infection, which remains one of the main causes of morbidity and death in these patients. Because the risk of nosocomial infection is the greatest during the first weeks after bone marrow transplantation when the patient is pancytopenic, modern bone marrow transplantation units have been established that include a "sterile" laminar air flow environment, antimicrobial gastrointestinal tract decontamination, use of "sterile" food, special equipment for patient monitoring, and trained personnel. Numerous studies have been published on the epidemiology of infections following bone marrow transplantation and associated risk factors [3] [4] [5] [6] [7] . However, despite the measures listed above, the incidence of infection remains high, and prevention appears difficult to achieve. To optimize antimicrobial therapy and pre-vention of infections, we retrospectively studied the epidemiology of bacterial, fungal, and viral infections in a retrospective cohort of 446 recipients of bone marrow transplants (BMTs) during a 4-year period.
PATIENTS AND METHODS
Recipients of BMTs are hospitalized in private rooms equipped with laminar air flow from the beginning of administration of the conditioning regimen to the recovery of an absolute neutrophil count of 11000 cells/mm 3 or, if the patient has GVHD, until the neutrophil count stabilizes. All patients had indwelling central venous catheters surgically inserted at the time of either the induction chemotherapy or the conditioning regimen. Care of the catheter site was usually performed twice weekly by use of aseptic methods, including the use of sterile gloves, mask, and gown. The same precautions were used when catheters were accessed for transfusion or perfusion. The catheter was usually removed 3 months after the patient underwent autologous transplantation and 6 months after the patient underwent allogeneic transplantation. However, the time of catheter removal can vary according to the time of engraftment and the occurrence of GVHD. Administration of hematopoietic growth factors to recipients of autologous BMTs was routinely initiated on day 6 or 7 after transplantation. No granulocytes or buffy coat preparations were transfused. The duration of neutropenia was defined as the number of days between transplantation and a finding of a stable neutrophil count of 11000 cells/mm 3 . GVHD prevention in recipients of allogeneic BMTs included the administration of both methotrexate and cyclosporin A. In the event of GVHD, patients received steroid therapy.
All patients received oral amphotericin B and gastrointestinal decontamination with oral vancomycin, colimycin, and tobramycin. Cotrimoxazole was administered for the prevention of infections with Pneumocystis species during the 2 days that preceded transplantation and from the time of discharge from the protected rooms until recovery of a CD4 lymphocyte count of у200 CD4 cells/mm 3 and/or cessation of immunosuppressive therapy in recipients of allogeneic BMTs.
Stool specimens were systematically collected twice weekly for the detection of colonization with Pseudomonas aeruginosa or fungi. Throat samples were collected at the time of mucositis. When a febrile episode (temperature of 138.5ЊC or of у38ЊC for 112 h) occurred, clinical examination, chest radiography, and sampling for culture of blood, urine, catheter, or other specimens were done before the patient started to receive empirical antimicrobial therapy. This broad-spectrum antimicrobial therapy was administered intravenously and included a combination of cefepim or piperacillin plus tazobactam and tobramycin. When the duration of fever was 12 days and was not documented, glycopeptides and/or iv amphotericin B were added to the treatment regimen. If the patient was known to be colonized with P. aeruginosa, amikacin with ceftazidime or imipenem was administered according to the susceptibility of the isolate. Acyclovir was added to the treatment regimen when patients had mucositis and/or results of serological tests that were positive for human herpesvirus type 1. Whenever possible, patients who were seronegative for cytomegalovirus received transplants of stem cells that were obtained from cytomegalovirus-negative donors and transfusions of blood and/or platelets that were obtained from cytomegalovirus-seronegative donors. Cytomegalovirus-negative patients who received transplants of stem cells that were obtained from cytomegalovirus-positive donors and cytomegalovirus-positive recipients of allografts were included in a protocol that used prophylactic valacyclovir. Ganciclovir was administered when cytomegalovirus was detected in 2 consecutive blood samples [8] .
Microbiological data were retrieved from the laboratory computerized database and merged with clinical data that were extracted from a bone marrow transplant registry database (Société Française de Greffe de Moelle). Microbiological data included the date of collection of the specimen, the body site, and the microorganism that was isolated. We included in this study all culture results obtained during the first 6 months after the patient underwent transplantation, for the diagnosis of bacterial infections, and during the first 12 months after the patient underwent transplantation, for the diagnosis of viral and fungal infections. Bacteremia was defined as a positive result of cultures of blood samples that were obtained through the indwelling central venous catheter or, more rarely, from a peripheral venipuncture. A catheter-related infection was defined as a positive result of culture of the tip of the catheter. After September 1994, cytomegalovirus viremia was systematically diagnosed by means of both culture and PCR [8] .
We assessed potential risk factors for bacteremia, cytomegalovirus viremia, and invasive infections with Candida and Aspergillus species by comparing the characteristics of the patients who had such infections with those of patients who were uninfected. The following potential risk factors were assessed: sex, age, nature and stage of the underlying disease, date and type of graft (allogeneic or autologous), use of peripheral blood progenitor cells (PBPCs) or bone marrow, use of hematopoietic growth factors, duration of neutropenia, type of conditioning chemotherapy, and, for allograft recipients, related or matched unrelated donor and grade of GVHD.
Data were analyzed by use of Epi Info, version 6.0 (Centers for Disease Control and Prevention). Fisher's 2-tailed exact test and the x 2 test were used to test for the significance of association.
RESULTS
Four hundred forty-six adult patients underwent stem cell transplantation at the Hotel Dieu Hospital in Nantes from 1993 through 1996; 92 patients (20.6%) received an allogeneic BMT and 354 patients (79.4%) received an autologous BMT.
Characteristics of recipients of autologous BMTs. Three hundred fifty-four patients received autologous transplants during the 4-year study period (table 1). A total of 247 patients (69.8%) received PBPC, 98 (27.7%) received bone marrow, and 9 (2.5%) received both PBPCs and bone marrow; 317 patients (89.5%) received either granulocyte colony-stimulating factor (298 patients; 94%) or granulocyte-macrophage colony-stimulating factor (19 patients; 6%). The median duration of neutropenia was 13 days (range, 4-46 days) in patients who were treated with hematopoietic growth factors and 17 days (range, 9-60 days) in patients who did not receive hematopoietic growth factors. At 6 months after transplantation, 317 (89.5%) of the recipients of autologous BMTs were alive, 30 (8.5%) had died, and 7 (2%) were lost to follow-up. Death was attributed to infection in 2 patients (0.6%; Aspergillus species in 1 patient and P. aeruginosa in 1 patient) who did not have other potentially fatal conditions.
Characteristics of recipients of allogeneic BMTs. Ninetytwo allogeneic bone marrow transplantations were performed during the 4-year study period (table 2) . Only 5 patients received PBPCs and all others received bone marrow; 18 recipients of allogeneic BMTs (19.6%) received hematopoietic growth factors. The median duration of neutropenia was 19 days (range, 7-136 days) in patients who did not receive hematopoietic growth factors and 18 days (range, 10-30 days) in patients who were treated with hematopoietic growth factors. Thirty-five recipients of allogeneic BMTs (38%) died during the first 6 months after transplantation; 14 deaths (40%) were attributed to infection (invasive aspergillosis in 12 patients [85.7%], 10 cases of which were documented and 2 of which were suspected but not proven; cytomegalovirus infection in 2 patients [14.3%]), despite the concurrent presence of either relapse of disease (in 3 patients) or GVHD (in 2).
Infection rates. A microbiologically documented infection occurred in 274 (61.4%) of all 446 recipients of BMTs. The most common infection was bacteremia, in 172 patients (incidence per 100 patients, 38.6%); followed by urinary tract infection, 64 episodes in 55 patients (incidence per 100 patients, 12.3%); cytomegalovirus viremia, in 22 patients (4.9%); invasive aspergillosis, in 13 patients (2.9%); catheter-related infection, in 9 patients (2%); and fungemia, in 4 patients (0.9%).
During the 4-year study period, the incidence of bacteremia was 55.8%, with 249 cases of bacteremia having occurred in 172 recipients of BMTs. Coagulase-negative staphylococci were the most common bacterial species isolated from blood samples, with an incidence of 34% (154 of 446 patients), followed by viridans streptococci (33 of 446), with an incidence of 7%. The incidence of bacteremia caused by other bacterial species was 2% (12 of 446 patients) for Staphylococcus aureus, 1.8% (8 of 446) each for Streptococcus species and Enterobacteriaceae, and 1.5% (7 of 446) for P. aeruginosa. Nineteen cultures of blood samples (incidence, 4.3%) yielded a gram-positive bacillus (Corynebacterium species in 15 cultures and Propionibacterium acnes in 4).
Catheter-related infections were diagnosed in 9 recipients of BMTs. Coagulase-negative staphylococci were the most common microorganism to have been isolated from cultures of the catheter tip (in 5 patients), followed by Candida (Candida albicans in 1 patient and Candida lipolytica in 1 patient). Four catheter infections due to coagulase-negative staphylococci and 2 due to Candida species were complicated by bloodstream infections. Two cultures of catheter tips yielded a gram-negative bacterium (Acinetobacter baumannii in 1 culture and Escherichia coli in 1), but they were not complicated by bacteremia.
All recipients of BMTs were colonized with fungi. C. albicans represented 55.5% of the fungi isolated, Candida species other than C. albicans represented 28% (Candida glabrata, 5.9%; Candida tropicalis, 3%; Candida krusei, 2.4%; Candida kefyr, 2%; other Candida species, 14.8%), Geotrichum species represented 9%, and Saccharomyces cerevisiae represented 7%. Different species of yeasts were frequently isolated from different body sites (cultures of stool, urine, and throat samples) from the same patient (table 3) . Only 4 cases of fungemia (incidence, 0.9%) were documented.
Invasive aspergillosis was documented in 13 patients (2.9%), 10 of whom had received allogeneic BMTs (10.8%) and 3 of whom had received autologous BMTs (0.8%), and the specimen that tested positive most often was that which had been obtained by means of bronchoalveolar lavage. Aspergillus fumigatus was isolated from 12 specimens, Aspergillus niger from 2, and Aspergillus nidulans from 1. Three cases of aspergillosis were diagnosed by means of direct examination; culture results, however, remained negative. Three different species of Aspergillus (A. nidulans, A. fumigatus, and A. niger) were isolated from a single bronchoalveolar lavage specimen obtained from 1 recipient of an allogeneic BMT.
A total of 102 viruses were isolated from 81 recipients of BMTs. Human herpesvirus type 1 represented 45% of the viruses isolated and was the virus most frequently cultured from oropharyngeal specimens, whereas cytomegalovirus, which represented 35% of the positive specimens, was the virus most frequently isolated from cultures of blood and urine samples. Twenty-two patients, 16 of whom had received allogeneic BMTs (17.4%) and 6 of whom had received autologous BMTs (1.7%), developed cytomegalovirus viremia.
Comparison between recipients of autologous BMTs and recipients of allogeneic BMTs. Sixty-eight of the 249 cases of bacteremia occurred in recipients of allogeneic BMTs, and 181 occurred in recipients of autologous BMTs. A total of 204 cases (81.9%) occurred before day 30 after transplantation, and 45 (18%) occurred after that day. During the period of neutropenia, coagulase-negative staphylococci were the bacterial species that were most frequently isolated from cultures of blood samples In recipients of autologous BMTs, 161 (89%) of 181 episodes of bacteremia occurred before day 15 after transplantation, during the period of neutropenia. After day 15, the incidence of bacteremia decreased; 6 (3.3%) of 181 cases of bacteremia occurred from day 15 through day 30 after transplantation, and 14 (7.7%) of 181 cases occurred more than 30 days after transplantation. In contrast, among recipients of allogeneic BMTs, 36 ; RR, 0.8). In contrast, after P p .3 the patients underwent engraftment, the risk of developing bacteremia was 5.9 times higher among recipients of allogeneic BMTs than it was among recipients of autologous BMTs (31 of 68 patients vs. 14 of 181 patients, respectively; P ! ; RR, 5.9; 95% CI, 3.35-10.4). .00000001
Patients were found to be colonized with fungi at a median time of 7 days after transplantation (range 0-261 days). Four cases of fungemia occurred in recipients of allogeneic BMTs; they were diagnosed on days 13, 33, 60, and 90 after transplantation. No cases of fungemia were diagnosed in recipients of autologous BMTs (4 of 92 patients vs. 0 of 354 patients, respectively;
; RR, undefined). P p .001 The median time of diagnosis of aspergillosis was day 88 after transplantation (range, day 9-176). Ten (77%) of 13 cases were diagnosed more than 30 days after transplantation, and 3 cases (23%) were diagnosed earlier, on days 9, 17, and 21 after transplantation. The cases of invasive aspergillosis in the 3 recipients of autologous BMTs were diagnosed on days 10, 17, and 365 after transplantation. The earliest diagnosis was made on day 10 after transplantation among recipients of autologous BMTs and on day 30 after transplantation among recipients of allogeneic BMTs (range, day 30-365). The risk of developing invasive aspergillosis was 12.8 times higher among recipients of allogeneic BMTs than it was among recipients of autologous BMTs (10 of 92 patients vs. 3 of 354 patients, respectively; RR, 12.8;
; 95% CI, 3.6-45.6). P p .000002 Nineteen (82.6%) of 23 cases of cytomegalovirus viremia occurred 130 days after transplantation. The median time of detection was at day 51 after transplantation (range, day 14 -365). In recipients of allogeneic BMTs, the median time of detection of cytomegalovirus viremia was day 57 after transplantation, and the earliest specimen to test positive was obtained on day 30 after transplantation, whereas in recipients of autologous BMTs, the median time of detection was day 34 after transplantation, and the earliest specimen to test positive was obtained on day 14 after transplantation. The risk of developing cytomegalovirus viremia was 10.2 times higher among recipients of allogeneic BMTs than it was among recipients of autologous BMTs (16 of 92 patients vs. 6 of 354 patients, respectively;
; RR, 10.2; 95% CI 4.1-25.5). P p .0000001 Assessment of risk factors for documented infections. We sought to assess risk factors for documented infections occurring in the whole population of BMT recipients by comparing the characteristics of infected patients with those of patients who did not develop infection. Subsequently, we assessed risk factors for infection separately in recipients of autologous and recipients of allogeneic BMTs, during and after the period of neutropenia.
During the period of neutropenia, none of the potential risk factors analyzed were significantly associated with bacteremia in BMT recipients. After the patients underwent engraftment, bacteremia was more common among recipients of autologous BMTs who did not receive hematopoietic growth factors ( ; RR, 8.1; 95% CI, 3.2-23.1) and among those P p .000007 who had a longer duration of neutropenia (median, 17 days vs. 13 days). No risk factor for bacteremia after engraftment was identified in recipients of allogeneic BMTs.
Acute leukemia was the only risk factor for invasive aspergillosis identified in recipients of allogeneic BMTs (8 of 10 vs. 42 of 82;
; RR, 3.36; 95% CI, 0.75-15). No risk factor P p .08 for invasive aspergillosis was identified in recipients of autologous BMTs.
No risk factors were significantly associated with cytomegalovirus viremia in both recipients of allogeneic BMTs and recipients of autologous BMTs. However, all 6 recipients of autologous BMTs and 14 of the 16 recipients of allogeneic BMTs had positive results of serological tests for cytomegalovirus before the graft. Two recipients of allogeneic BMTs had negative results of serological tests, but they received stems cells that were transplanted from a seropositive donor.
Surveillance cultures. We sought to assess the predictive value of surveillance cultures. Coagulase-negative staphylococci (60 [59.4%] of 101 cultures) and viridans streptococci (27 [26.7%] of 101 cultures) were the microorganisms most commonly isolated from cultures of throat samples. However, only 1 of the 25 patients with a throat culture result that was positive for viridans streptococci and 0 of the 54 patients with a throat culture result that was positive for coagulase-negative staphylococci subsequently developed bacteremia caused by these organisms. In contrast, the isolation of P. aeruginosa in stool was highly predictive of the occurrence of bacteremia, because the risk of developing P. aeruginosa bacteremia was 18.5 times higher in colonized patients (5 of 7 patients) than in noncolonized patients (2 of 393 patients;
; RR, 18.5; P p .00001 95% CI, 3.7-93.2).
Among the 4 patients who developed fungemia, 3 were colonized with the C. albicans isolate that was responsible for sepsis, and 1 patient was not colonized by the C. lipolytica organism that had caused fungemia.
DISCUSSION
Most epidemiological studies of recipients of BMTs either included only recipients of autologous BMTs or included recipients of allogeneic BMTs and recipients of autologous BMTs but only studied infections caused by few selected microorganisms. In contrast, our study describes all infectious episodes that occurred in a retrospective cohort of 446 recipients of either allogeneic BMTs or autologous BMTs during periods of neutropenia and after engraftment.
Unlike other studies [5] , we did not observe differences between persons who received allogeneic BMTs and those who received autologous BMTs during periods of neutropenia with regard to either the incidence of bacteremia or the bacterial species that was isolated. With regard to patients who underwent engraftment, our results are consistent with those published elsewhere [9] [10] [11] [12] [13] that show that bacteremia, invasive aspergillosis, and cytomegalovirus viremia were more common among recipients of allogeneic BMTs than they were among recipients of autologous BMTs.
No risk factor was identified during the period of neutropenia, in recipients of either autologous or allogeneic BMTs. Bacteremia was rare in recipients of autologous BMTs after they had undergone engraftment, with the exception of patients who did not receive hematopoietic growth factors. In contrast, bacteremia continued to occur in recipients of allogeneic BMTs after they had undergone engraftment. However, no risk factor was identified and, surprisingly, GVHD was not associated with the occurrence of bacteremia in recipients of allogeneic BMTs.
Because coagulase-negative staphylococci were the dominant species to have been isolated from blood samples obtained after neutropenia, we hypothesized that the higher incidence of bacteremia observed after engraftment, in recipients of allogeneic BMTs and in recipients of autologous BMTs who did not receive hematopoietic growth factors, was related to a later removal of the central venous catheter due to a longer duration of neutropenia and/or to the occurrence of GVHD and, therefore, a longer duration of central venous catheterization.
In our study, 2 of the 3 cases of invasive aspergillosis that were documented in recipients of autologous BMTs were diagnosed early after transplantation, whereas aspergillosis in recipients of allogeneic BMTs was diagnosed, at the earliest, on day 30 after transplantation. This bimodal distribution of invasive aspergillosis in recipients of BMTs has already been reported elsewhere [9, 14] . However, in our study, the number of recipients of autologous BMTs who developed invasive aspergillosis was too small to enable identification of risk factors. As has been reported elsewhere [9] , we found that invasive aspergillosis was significantly more common in recipients of allogeneic BMTs and in patients with acute leukemia than it was in recipients of autologous BMTs. However, the risk factors identified in other studies [9, [14] [15] [16] , such as the use of stem cells obtained from unrelated donors, occurrence of GVHD, or corticosteroid treatment, did not appear as risk factors in our study, probably because of the small number of cases of invasive aspergillosis that were diagnosed. This infection is still the leading cause of death in recipients of BMTs, because its diagnosis remains difficult and is often made late during the course of the disease. Therefore, there is an urgent need to improve detection and prevention of this toooften-fatal infection.
In this study, we tried to evaluate the value of surveillance cultures. With regard to coagulase-negative staphylococci and viridans streptococci, no association was found between a positive result of culture of throat samples and the occurrence of bacteremia.
As reported elsewhere [17] , the colonization of the digestive tract with P. aeruginosa was predictive of a later occurrence of P. aeruginosa bacteremia. The early administration of anti-Pseudomonas therapy, when a recipient of a BMT is known to be colonized, may explain the small number of patients who developed P. aeruginosa bacteremia.
The predictive value of colonization with Candida species for the occurrence of a fungemia is debated [18, 19] . The main problem is related to the difficulty in deciding when to prescribe antifungal agents, because in our study, almost all of the patients were colonized, whereas only 4 cases of fungemia were diagnosed during the 4-year period. Only improvement in detection of fungemia, by means of either PCR or antigenic detection, could enable optimization of prescription of amphotericin B and a better understanding of the role of colonization with this species.
Our results suggest that the empirical antimicrobial therapy should be the same for recipients of allogeneic BMTs and recipients of autologous BMTs during neutropenia. After they undergo engraftment, more attention should be paid to recipients of allogeneic BMTs, and the empirical antimicrobial therapy should include antibacterial agents, even if the patients no longer have neutropenia. The results of the surveillance cultures led us to stop systematically obtaining throat and stool specimens for the detection of coagulase-negative staphylococci, viridans streptococci, and fungi. In addition, the results of this study led us to remove central venous catheters as soon as possible, to discontinue the surveillance of cytomegalovirus in recipients of autologous BMTs, and to try to improve the diagnosis and the prognosis of invasive aspergillosis by performing a systematic detection of Aspergillus antigens and by using preemptive therapy with itraconazole. Most importantly, this retrospective study encouraged us to design a prospective study that focused on 2 main issues: examination of the clinical and molecular epidemiology of coagulase-negative staphylococcal bacteremia, to improve our understanding of their clinical significance and to limit glycopeptide prescription; and improvement of the diagnosis of fungal infections by assessing new methods of diagnosis.
